NCCN Receives $2-Million Funding Commitment from ImmunoGen, Inc. to Study Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Cancers

The NCCN Oncology Research Program (ORP) has received a $2-million grant from ImmunoGen, Inc. to facilitate preclinical and clinical research with mirvetuximab soravtansine for folate receptor alpha-positive cancers at NCCN Member Institutions and their affiliate community hospitals. FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from ImmunoGen, Inc. to support the advancement of scientific knowledg...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news